

PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

XHANCE
(fluticasone propionate nasal spray)

Status: CVS Caremark® Criteria

Type: Initial Prior Authorization with Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Chronic Rhinosinusitis with Nasal Polyps

Xhance is indicated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults.

Chronic Rhinosinusitis without Nasal Polyps

Xhance is indicated for the treatment of chronic rhinosinusitis without nasal polyps (CRSSNP) in adults.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the treatment of chronic rhinosinusitis with or without nasal polyps in an adult
 - AND**
 - The request is NOT for continuation of therapy
 - AND**
 - The patient has experienced an inadequate treatment response to an alternative intranasal corticosteroid therapy
 - OR**
 - The patient has experienced an intolerance to an alternative intranasal corticosteroid therapy
 - OR**
 - The patient is not a candidate for a trial with an alternative intranasal corticosteroid therapy
 - OR**
 - The request is for continuation of therapy
 - AND**
 - The patient has achieved or maintained a positive clinical response to the requested drug (i.e., improvement in nasal congestion, mucopurulent drainage, facial pain/pressure/fullness, sense of smell, improvement in polyp grade)

Quantity Limits apply.

2 packages of 16 mL each (32 mL) / 25 days* or 6 packages of 16 mL each (96 mL) / 75 days*

* The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

Duration of Approval (DOA):

- 4364-C: DOA: 12 months

REFERENCES

1. Xhance [package insert]. Yardley, PA: OptiNose US, Inc; March 2024.

Xhance PA with Limit Policy UDR 02-2024 v2.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

2. Lexicomp Online, Lexi-Drugs. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed December 28, 2023.
3. Mometasone Furoate [package insert]. Weston, FL: Apotex Corp.; September 2022.
4. Beconase AQ [package insert]. Research Triangle Park, NC: GlaxoSmithKline; February 2021.
5. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 12/28/2023).
6. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. *Otolaryngol Head Neck Surg*. 2015;152(2 Suppl):S1-S39.